Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTXNASDAQ:GNPXNASDAQ:JAGXNASDAQ:MBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsGNPXGenprex$2.13-4.1%$3.67$2.09▼$45.20$4.07M-0.6174,206 shs38,188 shsJAGXJaguar Health$0.16-11.3%$0.09$0.05▼$1.22$43.34M1.3550.67 million shs31.20 million shsMBIOMustang Bio$0.34-8.1%$1.04$0.33▼$8.17$3.55M1.58177,262 shs129,383 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%-33.75%GNPXGenprex0.00%-20.50%-34.62%-73.56%-94.42%JAGXJaguar Health+7.40%+64.74%+157.04%+74.83%-72.32%MBIOMustang Bio-3.39%-32.20%-64.50%-72.52%-90.82%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex4.2248 of 5 stars3.55.00.04.70.60.81.3JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio1.6467 of 5 stars3.55.00.00.01.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyxN/AN/AN/AN/AGNPXGenprex3.00Buy$10.00369.48% UpsideJAGXJaguar HealthN/AN/AN/AN/AMBIOMustang Bio3.00Buy$17.254,949.77% UpsideCurrent Analyst RatingsLatest GNPX, JAGX, APTX, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AGNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AJAGXJaguar Health$9.76M4.44N/AN/A$0.07 per share2.24MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AGNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)Latest GNPX, JAGX, APTX, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/AGNPXGenprexN/A2.312.31JAGXJaguar Health6.332.001.34MBIOMustang BioN/A0.740.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/AGNPXGenprex14.05%JAGXJaguar Health12.04%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%GNPXGenprex11.54%JAGXJaguar Health0.16%MBIOMustang Bio2.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableGNPXGenprex311.91 million1.69 millionOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataMBIOMustang Bio8010.39 million10.17 millionNot OptionableGNPX, JAGX, APTX, and MBIO HeadlinesSourceHeadlineWorcester biopharmaceutical firm Mustang Bio to lay off 81% of staffwbjournal.com - April 18 at 1:45 PMBiotech cites federal review of deal with Chinese firm in latest staff cutsbizjournals.com - April 16 at 9:03 AMMustang Bio stock tumbles 27% amid news of mass layoffsmsn.com - April 15 at 5:59 PMMustang Bio announces major workforce reductioninvesting.com - April 14 at 11:56 AMMustang Bio to Cut Global Headcount by 81%marketwatch.com - April 12 at 8:56 PMMustang Bio Exploring MB-106 CAR T-Cell Candidate in Autoimmune Diseasesprecisionmedicineonline.com - March 29 at 3:32 PMMustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseasesglobenewswire.com - March 28 at 9:00 AMMustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trialfiercebiotech.com - March 12 at 1:35 PMMustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 11 at 4:05 PMCAR T-Cell Therapy Shows Activity in Subgroup of Brain Tumor Patientstechnologynetworks.com - March 8 at 8:10 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Gliomatmcnet.com - March 7 at 9:09 AMWhy Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarketmarkets.businessinsider.com - March 7 at 9:09 AMMustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Gliomaglobenewswire.com - March 7 at 7:30 AMMustang Bio Inc (MBIO)uk.investing.com - February 13 at 2:36 PMMustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conferencefinance.yahoo.com - January 11 at 9:29 AMMustang Bio Inc MBIOmorningstar.com - January 6 at 12:54 AMMustang Bio Stock (NASDAQ:MBIO) Dividends: History, Yield and Datesbenzinga.com - December 27 at 10:10 PMMBIO Mustang Bio, Inc.seekingalpha.com - December 22 at 10:10 AMMustang Bio: Departure Of Directors Or Certain Officers; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officerscbonds.com - December 14 at 5:42 PMMustang Bio files to sell 2.74M shares of common stock for holdersmsn.com - December 12 at 1:26 PMMustang Bio’s Positive Financial Performance and Promising Clinical Developments Drive Buy Ratingmarkets.businessinsider.com - November 15 at 8:45 PMMustang Bio, Inc.: Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - November 15 at 3:44 PMMustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - November 2 at 10:51 AMMustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - October 30 at 3:45 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.